Abstract
Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti–PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.
Funding Information
  • National Cancer Institute
  • National Institutes of Health (R35 CA197633, P01 CA168585, 1U54 CA199090, R01 CA170689)
  • Stand Up To Cancer (SU2C-AACR-DT1012)
  • American Society of Clinical Oncology
  • Tower Cancer Research Foundation
  • The Hope Foundation
  • UCLA

This publication has 47 references indexed in Scilit: